Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Lung Neoplasms 22Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 12Fallopian Tube Neoplasms 11Carcinoma, Hepatocellular 9Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Mycosis Fungoides 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Colonic Neoplasms 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Sezary Syndrome 3Rectal Neoplasms 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Endometrial Neoplasms 3Cholangiocarcinoma 3

Interventions

Gemcitabine 33Cisplatin 28pembrolizumab 19durvalumab 17Oxaliplatin 16Fluorouracil 16Leucovorin 14Magnetic Resonance Spectroscopy 13Specimen Handling 9Biopsy 9lenvatinib 7Nivolumab 7Capecitabine 7Taxes 6Paclitaxel 6Irinotecan 6fludarabine 5Folfox protocol 5Drug Therapy 5Carboplatin 5Albumin-Bound Paclitaxel 5pemigatinib 4Ipilimumab 4Fluorodeoxyglucose F18 4Floxuridine 4Cyclophosphamide 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Disulfides × 1 year × Clear all
NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Not yet recruiting
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Recruiting
16 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡